Andrea Lobo, PhD,  science writer—

A Phase 1/2 trial testing Cabaletta Bio’s CAR T-cell therapy, rese-cel (resecabtagene autoleucel), in adults with hard-to-treat systemic sclerosis (SSc) is recruiting patients at several sites in the U.S. The open-label RESET-SSc trial (NCT06328777) is assessing the safety and efficacy of rese-cel as a single infusion into…

Treatment with Ofev (nintedanib) for up to four years was associated with a sustained slowing of lung function decline in people with systemic sclerosis (SSc) associated with interstitial lung disease (SSc-ILD). That’s according to new results from the open-label study SENSCIS-ON (NCT03313180), a three-year extension of the…

Low levels of a type of white blood cell called natural killer (NK) cells may help diagnose pulmonary arterial hypertension (PAH) in people with systemic sclerosis (SSc), a study in China suggests. In PAH, the blood vessels that supply blood to the lungs, called pulmonary arteries, narrow, restricting…

Autotaxin, a protein involved in wound healing and scarring, or fibrosis, was found at higher levels in women with systemic sclerosis-associated interstitial lung disease (SSc-ILD) than in men with the condition, per a new U.S. study. According to the researchers, “this study is the first to report sex-specific ……

Zura Bio has launched a Phase 2 trial to evaluate the safety and efficacy of tibulizumab, its experimental dual pathway antibody to treat systemic sclerosis (SSc). The TibuSURE trial is expected to enroll as many as 80 adults with early diffuse cutaneous SSc. They will receive tibulizumab…

Fatigue levels in people with scleroderma, also known as systemic sclerosis or SSc, are tied to several social, demographic, lifestyle, and disease-related factors, according to a study by a multinational team of researchers. Smoking, higher body mass index (BMI) —…

The specific self-reactive antibodies (autoantibodies) of people with systemic sclerosis (SSc) overlap syndrome — a condition in which SSc patients have clinical signs and autoantibodies related to other connective tissue diseases — are tied to organ damage and SSc prognosis, according to a single-center study in China. Patients with…

The Scleroderma Research Foundation (SRF) has announced the star-studded lineup for its annual Cool Comedy, Hot Cuisine fundraising event, slated to take place Oct. 29 at the Fairmont Century Plaza in Los Angeles. The event will be hosted by actor and comedian Jeff Ross, known as the “…

Patients with systemic sclerosis (SSc) who have a stem cell transplant see normalized gene activity related to immune function up to 4.5 years after the procedure. That’s according to recent data from samples in the Phase 2/3 SCOT trial (NCT00114530), wherein the potential benefits of a stem cell…

CONQUEST, a platform clinical trial launched by the Scleroderma Research Foundation (SRF), is now enrolling people with interstitial lung disease associated with systemic scleroderma (SSc-ILD) at centers in the U.S. The study is analyzing two investigational therapies using a master protocol to compare both treatments with a…